Telaprevir-related dermatitis.

PubWeight™: 0.98‹?› | Rank: Top 15%

🔗 View Article (PMID 23560295)

Published in JAMA Dermatol on February 01, 2013

Authors

Jean-Claude Roujeau1, Maja Mockenhaupt, Steven R Tahan, Joshua Henshaw, Emily C Martin, Matt Harding, Ben van Baelen, Leif Bengtsson, Priya Singhal, Robert S Kauffman, Robert S Stern

Author Affiliations

1: Department of Dermaology, Université Paris-Est, Créteil, France.

Articles by these authors

Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21

Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33

Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31

Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol (2005) 3.04

Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol (2007) 2.77

Neuropsychological measures in normal individuals that predict subsequent cognitive decline. Arch Neurol (2007) 2.77

Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol (2007) 2.71

Neurolymphomatosis. Neuro Oncol (2003) 2.68

Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol (2002) 2.49

Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study. J Invest Dermatol (2011) 2.45

Increased expression of stem cell markers in malignant melanoma. Mod Pathol (2006) 2.39

Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum (2009) 2.38

Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med (2013) 2.25

Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study. J Invest Dermatol (2010) 2.18

Topical calcineurin inhibitors labeling: putting the "box" in perspective. Arch Dermatol (2006) 2.16

Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses (2008) 2.01

Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol (2004) 1.94

A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics (2008) 1.92

How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol (2009) 1.87

Clinical severity of psoriasis in last 20 years of PUVA study. Arch Dermatol (2007) 1.83

Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat Biotechnol (2011) 1.79

The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol (2005) 1.68

Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis (2013) 1.62

Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology (2011) 1.62

Impact of psoriasis on health-related quality of life decreases over time: an 11-year prospective study. J Invest Dermatol (2006) 1.57

Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology (2011) 1.57

Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics (2009) 1.53

The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study. J Invest Dermatol (2003) 1.53

Members of the national psoriasis foundation: more extensive disease and better informed about treatment options. Arch Dermatol (2005) 1.45

Follicular malignant melanoma: a case report of a metastatic variant and review of the literature. J Am Acad Dermatol (2011) 1.39

Images in HIV/AIDS. Sweet syndrome and syphilis in an HIV-infected person. AIDS Read (2008) 1.39

HHV8 is not limited to Kaposi's sarcoma. Mod Pathol (2005) 1.38

Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol (2004) 1.29

Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol (2013) 1.28

Severe cutaneous reactions to sulfadoxine-pyrimethamine and trimethoprim-sulfamethoxazole in Blantyre District, Malawi. Am J Trop Med Hyg (2006) 1.24

Sphingosine 1-phosphate induces chemotaxis of immature and modulates cytokine-release in mature human dendritic cells for emergence of Th2 immune responses. FASEB J (2002) 1.24

Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS One (2012) 1.19

Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol (2005) 1.16

Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents. AIDS (2009) 1.13

Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis. J Invest Dermatol (2013) 1.12

Bullous pemphigoid therapy -- think globally, act locally. N Engl J Med (2002) 1.09

Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol (2011) 1.07

Spontaneous adverse event reports of Stevens-Johnson syndrome/toxic epidermal necrolysis: detecting associations with medications. Pharmacoepidemiol Drug Saf (2011) 1.04

Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS (2007) 1.03

Characterization of the biological activities of uridine diphosphate in human dendritic cells: Influence on chemotaxis and CXCL8 release. J Cell Physiol (2004) 0.99

A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection. PLoS Comput Biol (2012) 0.98

The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective. J Rheumatol (2003) 0.97

Reported use of photosensitizing medications and basal cell and squamous cell carcinoma of the skin: results of a population-based case-control study. J Invest Dermatol (2007) 0.96

Expression and function of histamine receptors in human monocyte-derived dendritic cells. J Allergy Clin Immunol (2002) 0.95

Accuracy of biopsy sampling for subtyping basal cell carcinoma. J Am Acad Dermatol (2011) 0.95

Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes. Intensive Care Med (2009) 0.95

Lysophosphatidic acid induces chemotaxis, oxygen radical production, CD11b up-regulation, Ca2+ mobilization, and actin reorganization in human eosinophils via pertussis toxin-sensitive G proteins. J Immunol (2004) 0.93

Use of in vivo confocal microscopy in malignant melanoma: an aid in diagnosis and assessment of surgical and nonsurgical therapeutic approaches. Arch Dermatol (2004) 0.92

"Nevus/melanocytoma/melanoma": that which we call a rose by any other name would smell as sweet. Arch Pathol Lab Med (2012) 0.91

Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe. Orphanet J Rare Dis (2011) 0.91

C-Kit (CD117) expression in AIDS-related, classic, and African endemic Kaposi sarcoma. Appl Immunohistochem Mol Morphol (2005) 0.88

Telaprevir: pharmacokinetics and drug interactions. Antivir Ther (2012) 0.88

Review of drug interactions with telaprevir and antiretrovirals. Antivir Ther (2013) 0.88

Expression of neurotrophin receptor Trk-C in nevi and melanomas. J Cutan Pathol (2003) 0.87

Granulomatous and suppurative dermatitis at interferon alfa injection sites: report of 2 cases. J Am Acad Dermatol (2002) 0.87

Dermatologic changes induced by repeated Ixodes scapularis bites and implications for prevention of tick-borne infection. Vector Borne Zoonotic Dis (2009) 0.87

The influence of lysophosphatidic acid on the functions of human dendritic cells. J Immunol (2002) 0.87

Severe drug-induced skin reactions: clinical features, diagnosis, etiology, and therapy. J Dtsch Dermatol Ges (2015) 0.87

Nano-biosensor development for bacterial detection during human kidney infection: use of glycoconjugate-specific antibody-bound gold NanoWire arrays (GNWA). Glycoconj J (2004) 0.86

Matrix metalloproteinases in the progression and regression of Kaposi's sarcoma. J Cutan Pathol (2006) 0.86

High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients. J Invest Dermatol (2005) 0.85

Tumor necrosis factor alpha induces upregulation of CXC-chemokine receptor type II expression and magnifies the proliferative activity of CXC-chemokines in human melanocytes. Eur J Dermatol (2003) 0.84

Histological characterization of regression in acquired immunodeficiency syndrome-related Kaposi's sarcoma. J Cutan Pathol (2004) 0.84

Stevens-Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy. Radiother Oncol (2008) 0.83

Investigation into the multidimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics (2007) 0.82

Histopathologic manifestations of systemic diseases: the example of cutaneous lupus erythematosus. J Cutan Pathol (2010) 0.82

Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study. J Burn Care Res (2011) 0.81

Low-affinity nerve growth factor receptor (P75 NGFR) as a marker of perineural invasion in malignant melanomas. J Cutan Pathol (2009) 0.81

Use of biological agents in patients with moderate to severe psoriasis: a cohort-based perspective. Arch Dermatol (2007) 0.81

Impact of bar-code labeling of clinical photographs on patient care and practice workflow. Arch Dermatol (2012) 0.81

Black thyroid. Ear Nose Throat J (2003) 0.81

Death ligand TRAIL, secreted by CD1a+ and CD14+ cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis. Exp Dermatol (2011) 0.81

The psychometric properties of the psoriasis disability index in United States patients. J Invest Dermatol (2005) 0.81

Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity. J Clin Gastroenterol (2015) 0.80

Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol (2003) 0.80

Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders. Hepatology (2009) 0.80

Futility rules for telaprevir combination treatment for patients with hepatitis C virus infection. Clin Gastroenterol Hepatol (2012) 0.80

Allergological approach to drug hypersensitivity reactions. J Dtsch Dermatol Ges (2008) 0.80

A randomized, controlled trial of four ablative fractionated lasers for photoaging: a quadrant study. Dermatol Surg (2012) 0.79

Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C. J Hepatol (2007) 0.79

A promising step forward in psoriasis therapy. JAMA (2003) 0.79

Stevens-Johnson syndrome/toxic epidermal necrolysis: are drug dictionaries correctly informing physicians regarding the risk? Drug Saf (2013) 0.79

STROBE: a Beacon for observational studies. Arch Dermatol (2008) 0.78

The misperception that clinical trial data reflect long-term drug safety: lessons learned from Efalizumab's withdrawal. Arch Dermatol (2009) 0.78

Topical tretinoin, another failure in the pursuit of practical chemoprevention for non-melanoma skin cancer. J Invest Dermatol (2012) 0.78

Psoralen plus ultraviolet A does not increase the risk of cataracts: a 25-year prospective study. J Am Acad Dermatol (2007) 0.78

A single-center open-label long-term comparison of tacrolimus ointment and topical corticosteroids for treatment of atopic dermatitis. J Dtsch Dermatol Ges (2008) 0.78

Going beyond associative studies of psoriasis and cardiovascular disease. J Invest Dermatol (2012) 0.77

Cellular senescence as a possible mechanism for halting progression of keloid lesions. Genes Cancer (2011) 0.77